DexCom, Inc.

DXCM

US2521311074

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-09 pm EDT			5-day change	1st Jan Change
110.8 ^USD	-0.12%		-1.47%	-10.68%

Jun. 26	Wall Street: up, on the edge, despite rates	CF
Jun. 25	Out with AI, in with defensive stocks

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

January 08, 2024 at 08:00 am EST

DexCom, Inc. provided revenue guidance for the full year of 2024. For the year, company expects total revenue of approximately $4.15 billion to $4.35 billion.

Latest news about DexCom, Inc.

Wall Street: up, on the edge, despite rates	Jun. 26	CF
Out with AI, in with defensive stocks	Jun. 25
Glucotrack Announces the Appointment of Andy Balo to Board of Directors	Jun. 20	CI
Dexcom Expands Aid Partnership into the Netherlands	Jun. 20	CI
Dexcom Showcases Extensive Clinical Data At ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People with Type 2 Diabetes	Jun. 20	CI
Tandem Diabetes Care, Inc. and Dexcom, Inc. Enter into Amended and Restated Development Agreement to Original Development Agreement and Amended and Restated Commercialization Agreement to Original Commercialization Agreement	Jun. 18	CI
Transcript : DexCom, Inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-05-2024 03:20 PM	Jun. 05
Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects Directly to Apple Watch in the United States	Jun. 05	CI
Dexcom Wins Access to Dexcom One for 100,000 People Living with Type 2 Diabetes	Jun. 04	CI
Nova Scotia Now Providing Coverage for Dexcom Continuous Glucose Monitoring Systems	Jun. 03	CI
Redburn Atlantic Initiates DexCom With Neutral Rating, $130 Price Target	May. 30	MT
Declaration of Voting Results by DexCom, Inc	May. 24	CI
Declaration of Voting Results by DexCom, Inc	May. 24	CI
Bio Conscious Announces Strategic Api Integration with Dexcom That Will Elevate the Current Level of Care for Diabetes Patients in Clinical Settings	May. 16	CI
Glutality Powered by StrideMD Announces Integration with Dexcom to Enhance Remote Diabetes Care with CGM Technology	Apr. 30	CI
Wall Street: the worst week of 2024 is followed by the best	Apr. 26	CF
Morgan Stanley Adjusts DexCom's Price Target to $132 From $122	Apr. 26	MT
Canaccord Genuity Adjusts Price Target on DexCom to $145 From $144	Apr. 26	MT
Raymond James Adjusts DexCom Price Target to $160 From $151	Apr. 26	MT
Dexcom's profit beats estimates on strong glucose monitor demand	Apr. 25	RE
DexCom, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
DexCom Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Gains; Shares Fall After Hours	Apr. 25	MT
Transcript : DexCom, Inc., Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
Earnings Flash (DXCM) DEXCOM Posts Q1 EPS $0.32, vs. Street Est of $0.27	Apr. 25	MT
Earnings Flash (DXCM) DEXCOM Posts Q1 Revenue $921M, vs. Street Est of $910.9M	Apr. 25	MT

DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 72.5% of net sales.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

DexCom is still in the running

March 07, 2024 at 04:49 am EST

More Strategies

Ratings for DexCom, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

110.8 USD

Average target price

150.3 USD

Spread / Average Target

+35.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
DEXCOM, INC.	-10.68%	44.08B
ABBOTT LABORATORIES	-7.66%	177B
MEDTRONIC PLC	-6.68%	98.58B
BECTON, DICKINSON AND COMPANY	-9.17%	64.01B
CENCORA, INC.	+8.27%	43.79B
HOYA CORPORATION	+17.11%	43.36B
METTLER-TOLEDO INTERNATIONAL, INC.	+7.84%	27.94B
TERUMO CORPORATION	+22.05%	25.79B
WEST PHARMACEUTICAL SERVICES, INC.	-9.51%	23.21B
ZIMMER BIOMET HOLDINGS, INC.	-13.10%	21.76B

Other Medical Equipment, Supplies & Distribution

DexCom, Inc.

Equities

DXCM

US2521311074

Medical Equipment, Supplies & Distribution

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

Latest news about DexCom, Inc.

Chart DexCom, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for DexCom, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Medical Equipment, Supplies & Distribution